Mumbai Reports 53 New COVID Cases Amid Asia Wave
Two COVID-positive patients passed away recently at Mumbai's KEM Hospital. However, doctors clarified that their deaths were due to pre-existing conditions—oral cancer and nephrotic syndrome—and not directly linked to COVID-19.

Advertisement
Mumbai, Maharashtra – Mumbai reported 53 new coronavirus cases on Monday, May 19, 2025, amid rising COVID infections in several Asian countries including Singapore, Hong Kong, China, and Thailand. While the Brihanmumbai Municipal Corporation (BMC) advises residents to remain calm, monitor their health closely, and seek medical care if symptoms appear, authorities are closely watching the situation to prevent any resurgence.
Two COVID-positive patients passed away recently at Mumbai’s KEM Hospital. However, doctors clarified that their deaths were due to pre-existing conditions—oral cancer and nephrotic syndrome—and not directly linked to COVID-19. This highlights the ongoing need for careful health monitoring, especially among vulnerable groups.
Rising COVID Cases Across Asia Spark Concerns
Asia is witnessing an increase in COVID cases, particularly in Singapore, which reported 3,000 new cases between May 1 and May 19—a 28% jump compared to the last week of April’s 11,100 cases. Hong Kong has recorded 81 cases since January, along with 30 deaths. China and Thailand have issued warnings following a doubling of positive tests, though exact case numbers remain undisclosed.
India has reported 257 cases between January 1 and May 19, 2025, with no indication of a new wave. The Ministry of Health and Family Welfare maintains that the COVID-19 situation in India is currently under control, with no significant surge detected. Nevertheless, health experts urge caution due to the rising cases in neighboring countries and recommend vaccinations and boosters.
New Omicron Variant JN1 Drives Current Infections
The recent infections in Asia and India have been linked to a new Omicron subvariant named JN1, alongside sub-variants LF7 and NB1.8. First identified in August 2023 and classified by the WHO as a “Variant of Interest” in December 2023, JN1 carries about 30 mutations. These mutations potentially weaken the immune system, making people with compromised immunity more susceptible.
Studies by Johns Hopkins University indicate that JN1 spreads more easily than earlier variants but is less likely to cause severe disease. Symptoms vary from a few days to several weeks, and prolonged symptoms may lead to “long-COVID,” where effects persist beyond initial recovery.
Vaccines and Boosters: Protection Against JN1
While existing vaccines are somewhat less effective at neutralizing the JN1 variant, the XBB.1.5 monovalent booster vaccine shows promising results. Designed specifically to target the XBB.1.5 Omicron sub-variant, this booster can increase antibody levels and reduce the risk of disease caused by JN1 by 19% to 49%. Public health officials are encouraging eligible populations to receive booster doses to strengthen immunity.
India’s COVID Journey and Ongoing Vigilance
Since the pandemic began in January 2020, India has endured three major COVID waves:
First wave (Jan 2020–Feb 2021): Approximately 1.08 crore cases, with a peak of 98,000 daily cases in September 2020 and 1.55 lakh deaths.
Second wave (Mar–May 2021): The deadliest phase driven by the Delta variant, with 1.69 lakh deaths and severe healthcare system strain.
Third wave (Dec 2021–Feb 2022): Caused by the Omicron variant, which was highly contagious but less severe, with 10,465 deaths and about 50 lakh new cases.
Overall, India has lost over 5 lakh lives to COVID-19, but the current phase shows no major surge. Health authorities stress that preventive measures, including vaccination, mask-wearing in crowded places, and timely medical intervention, remain critical.
Advertisement